渤健Biogen (BIIB) 2019年年度报告「NASDAQ」.pdf

1、Biogen 2019 Annual Report ANNUALREPORT2019 Concept,design and realization PETRANIX Corporate and Financial Communications AGAdliswil,Zurich SPrintingDonnelley Financial Solutions,PERFORMANCE HIGHLIGHTSFree Cash Flow 1,3 ($inmillions)Total Revenues ($inmillions)GAAP Diluted EPS/Non-GAAP Diluted EPS 1

2、Product Revenues($inmillions and%of total product revenues)Product Revenues by Region(%of total product revenues)U.S.Rest of the worldTECFIDERA$4,433$4,27438.95%39.3%VUMERITY5$6 0.05%Other4$851$6627.5%6.1%Interferon6$2,102$2,36318.5%21.7%TYSABRI$1,892$1,86416.6%17.1%SPINRAZA$2,097$1,72418.4%15.8%201

3、9201859%201941%100%total renewal electricity purchased by Biogen46%of manager-level and above positions held by women+4.5%increase in total product revenues year over year201768%32%201863%37%20152016201720182019$10,764$11,449$12,274$14,378$13,45320152016201720182019$17.01$20.22$15.34$16.93$11.922$21

4、.582$21.81$26.20$31.42$33.5720152016201720182019$2,223$2,706$2,484$3,917$6,2641 Non-GAAP diluted earnings per share(EPS)and Free Cash Flow are Non-GAAP financial measures.A reconciliation of GAAP to Non-GAAP diluted EPS and Free Cash Flow amounts is set forth on pages 913 of this Annual Report.2 GAA

5、P diluted EPS for 2018 and 2017 includes charges of$125 million and$1,176million,respectively,related to the impact of the Tax Cuts and Jobs Act of 2017.3 Free Cash Flow for 2016 through 2019 reflects an increase in capital expenditures related to the construction of our large-scale biologics manufa

6、cturing facility in Solothurn,Switzerland.4 For 2019 and 2018 Other includes product revenues from FAMPYRA,FUMADERM,BENEPALI,FLIXABI and IMRALDI.For 2018 Other also includes product revenues from ZINBRYTA,which was voluntary withdrawn from the market in March 2018.5 VUMERITY was approved by the U.S.